Premium
Influence of menstrual cycle and gender on alprazolam pharmacokinetics
Author(s) -
Kirkwood Cynthia,
Moore Andrea,
Hayes Peggy,
DeVane C Lindsay,
Pelonero Anthony
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.157
Subject(s) - alprazolam , pharmacokinetics , menstrual cycle , luteal phase , follicular phase , medicine , practolol , pharmacology , clinical pharmacology , endocrinology , hormone , propranolol , psychiatry , anxiety
The effects of menstrual cycle phases and gender on alprazolam pharmacokinetics were evaluated in normal volunteers. Alprazolam (1 mg) was administered to seven women during the late follicular and luteal phases of the menstrual cycle and to eight men on one occasion. No difference in alprazolam pharmacokinetic parameters was observed during the menstrual cycle phases. Mean alprazolam clearance (±SD) was 0.0037 ± 0.0009 ml/hr during the follicular phase and 0.0036 ± 0.001 ml/hr during the luteal phase ( p > 0.05, difference not significant). With use of weight as a covariant, there was no difference in alprazolam pharmacokinetic parameters between women and men. Mean alprazolam clearance (±SD) was 0.0036 ± 0.0009 ml/hr in women compared with 0.0041 ± 0.0006 ml/hr in men ( p > 0.05, difference not significant). Although alprazolam metabolism was similar on the 2 days tested, alterations may occur at other times during the menstrual cycle. Further investigation is needed to understand the effects of menstrual cycle phases and gender on drug metabolism. Clinical Pharmacology and Therapeutics (1991) 50, 404–409; doi: 10.1038/clpt.1991.157